8-K: Pulmonx Reports Mixed Q2 2025 Results, Revises Full-Year Revenue Guidance Downward

Pulmonx Corporation announced its second quarter 2025 financial results, reporting strong international revenue growth but revising its full-year revenue guidance lower due to slower U.S. market conversion.

Summary

• Worldwide revenue reached $23.9 million in Q2 2025, a 15% increase year-over-year, or 13% on a constant currency basis.
• International revenue grew significantly by 32% year-over-year to $9.1 million, or 27% on a constant currency basis.
• U.S. revenue increased by 6% year-over-year to $14.7 million.
• Gross margin for the quarter was 72%, a decrease from 74% in Q2 2024.
• Operating expenses rose 3% to $32.0 million.
• Net loss was $15.2 million, or $0.38 per share, slightly improved from a $15.3 million net loss ($0.39 per share) in Q2 2024.
• Adjusted EBITDA loss increased to $8.4 million from $7.6 million in the prior year period.
• Cash, cash equivalents, and marketable securities totaled $84.2 million as of June 30, 2025.
• Full-year 2025 revenue guidance was revised downwards to a range of $90 million to $92 million, from the previous $96 million to $98 million.
• Full-year 2025 operating expense guidance was revised downwards to $128 million to $130 million, from the prior $133 million to $135 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the downward revision of full-year revenue guidance and an increased Adjusted EBITDA loss, despite strong international growth and positive strategic initiatives. The U.S. market's slower-than-expected conversion is a significant concern.

Positives

• Worldwide revenue increased by 15% year-over-year to $23.9 million.
• International revenue demonstrated strong growth, increasing 32% year-over-year to $9.1 million.
• Net loss slightly improved to $15.2 million ($0.38 per share) from $15.3 million ($0.39 per share) in the prior year.
• Over 20,000 first-time patient engagements were driven through targeted Direct-to-Patient advertising.
• Added 12 new Zephyr Valve U.S. treatment centers and trained 26 new physicians, expanding market access.
• Revised full-year operating expense guidance downwards, indicating cost management efforts.

Negatives

• Full-year 2025 revenue guidance was revised downwards to $90 million $92 million from $96 million $98 million.
• Gross margin decreased to 72% in Q2 2025 from 74% in Q2 2024.
• Adjusted EBITDA loss increased to $8.4 million from $7.6 million in the same period last year.
• U.S. revenue growth was a more modest 6% compared to the strong international performance.
• Revenue conversion from U.S. initiatives is taking longer than expected.

Risks

• Longer-than-expected revenue conversion from U.S. initiatives could continue to impact financial performance.
• Potential impact from future tariffs or trade policy changes.
• Effects on the global macroeconomic environment, including foreign currency fluctuations, could negatively affect results.

Future Outlook

Pulmonx revised its full-year 2025 revenue guidance to a range of $90 million to $92 million, down from prior expectations of $96 million to $98 million, attributing this to longer-than-expected revenue conversion from U.S. initiatives. The company expects full-year gross margin to be approximately 74% and revised total operating expenses to fall within $128 million to $130 million, a decrease from prior guidance. This guidance does not account for potential impacts from future tariffs, trade policy changes, or global macroeconomic factors including foreign currency fluctuations.

Management Comments

• Steve Williamson, President and CEO, stated, "Strong international performance drove double-digit growth and provided a solid foundation for the quarter."
• Williamson noted, "While we are revising full-year guidance to reflect longer-than-expected revenue conversion from our U.S. initiatives, we are seeing early signs of traction."
• Williamson added, "Our efforts to build a scalable ecosystem by improving patient identification, access, and engagement, are beginning to deliver results and position us for sustained, long-term growth."

Industry Context

Pulmonx operates in the minimally invasive treatment sector for chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's strong international growth suggests robust demand for its Zephyr Valve in global markets, aligning with a broader trend of increasing adoption of less invasive medical procedures. However, the challenges in U.S. revenue conversion indicate potential market specific hurdles or slower adoption rates compared to international counterparts, possibly due to differing healthcare system dynamics, reimbursement landscapes, or competitive pressures within the U.S. market for lung disease treatments.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. Therefore, a direct assessment of results in the context of global benchmarks is not possible based solely on the provided information.

Stakeholder Impact

• Shareholders may experience negative sentiment due to the downward revision of full-year revenue guidance and increased Adjusted EBITDA loss, potentially impacting stock price.
• Patients may benefit from the company's continued efforts to improve patient identification, access, and engagement, as well as the expansion of U.S. treatment centers and trained physicians.
• Employees are likely to continue their focus on U.S. market initiatives and international growth strategies.

Next Steps

• Pulmonx will host a conference call on July 30, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter financial results.

Key Dates

Recommendation

While Pulmonx demonstrated robust international revenue growth and made progress in expanding its U.S. treatment network and patient engagement, the downward revision of its full-year revenue guidance due to slower U.S. market conversion is a significant concern. The increased Adjusted EBITDA loss also indicates ongoing challenges in achieving profitability. Investors should hold to monitor the effectiveness of the company's U.S. initiatives and assess if the revised guidance is achievable, as well as the trajectory towards sustainable profitability.

Keywords

Pulmonx, LUNG, COPD, Emphysema, Zephyr Valve, Minimally Invasive Treatment, Medical Devices, Financial Results, Earnings, Revenue Guidance, Healthcare